BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rosenzweig EB, Abman SH, Adatia I, Beghetti M, Bonnet D, Haworth S, Ivy DD, Berger RMF. Paediatric pulmonary arterial hypertension: updates on definition, classification, diagnostics and management. Eur Respir J 2019;53:1801916. [PMID: 30545978 DOI: 10.1183/13993003.01916-2018] [Cited by in Crossref: 152] [Cited by in F6Publishing: 180] [Article Influence: 50.7] [Reference Citation Analysis]
Number Citing Articles
1 Sullivan RT, Tandel MD, Bhombal S, Adamson GT, Boothroyd DB, Tracy M, Moy A, Hopper RK. Role of left atrial hypertension in pulmonary hypertension associated with bronchopulmonary dysplasia. Front Pediatr 2022;10:1012136. [DOI: 10.3389/fped.2022.1012136] [Reference Citation Analysis]
2 Xu Z, Zhang H, Arvanitaki A, Zhang C, Li Q, Keller BB, Gu H. Right Heart Catheterization in Pediatric Pulmonary Arterial Hypertension: Insights and Outcome from a Large Tertiary Center. JCM 2022;11:5374. [DOI: 10.3390/jcm11185374] [Reference Citation Analysis]
3 Fleming TR, Garnett CE, Conklin LS, Corriol-Rohou S, Hariharan S, Hsu D, Mueller-Velten G, Mulugeta Y, Portman R, Rothmann MD, Stockbridge NL, Wandel S, Zhang J, Yao L. Innovations in Pediatric Therapeutics Development: Principles for the Use of Bridging Biomarkers in Pediatric Extrapolation. Ther Innov Regul Sci 2022. [PMID: 36057747 DOI: 10.1007/s43441-022-00445-6] [Reference Citation Analysis]
4 Villafranco N, Chartan C, Varghese NP, Coleman RD. Tracheostomy in Pulmonary Hypertension: Not for the Faint of Heart. Pediatr Crit Care Med 2022;23:754-6. [PMID: 36053037 DOI: 10.1097/PCC.0000000000003021] [Reference Citation Analysis]
5 Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, Carlsen J, Coats AJS, Escribano-Subias P, Ferrari P, Ferreira DS, Ghofrani HA, Giannakoulas G, Kiely DG, Mayer E, Meszaros G, Nagavci B, Olsson KM, Pepke-Zaba J, Quint JK, Rådegran G, Simonneau G, Sitbon O, Tonia T, Toshner M, Vachiery JL, Vonk Noordegraaf A, Delcroix M, Rosenkranz S; ESC/ERS Scientific Document Group. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2022:2200879. [PMID: 36028254 DOI: 10.1183/13993003.00879-2022] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, Carlsen J, Coats AJS, Escribano-Subias P, Ferrari P, Ferreira DS, Ghofrani HA, Giannakoulas G, Kiely DG, Mayer E, Meszaros G, Nagavci B, Olsson KM, Pepke-Zaba J, Quint JK, Rådegran G, Simonneau G, Sitbon O, Tonia T, Toshner M, Vachiery JL, Vonk Noordegraaf A, Delcroix M, Rosenkranz S; ESC/ERS Scientific Document Group . 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 2022:ehac237. [PMID: 36017548 DOI: 10.1093/eurheartj/ehac237] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
7 Hopper RK, Abman SH, Elia EG, Avitabile CM, Yung D, Mullen MP, Austin ED, Bates A, Handler SS, Feinstein JA, Ivy DD, Kinsella JP, Mandl KD, Raj JU, Sleeper LA; Pediatric Pulmonary Hypertension Network Investigators. Pulmonary Hypertension in Children with Down Syndrome: Results from the Pediatric Pulmonary Hypertension Network Registry. J Pediatr 2022:S0022-3476(22)00762-4. [PMID: 36027975 DOI: 10.1016/j.jpeds.2022.08.027] [Reference Citation Analysis]
8 Bhombal S, Patel N. Diagnosis & management of pulmonary hypertension in congenital diaphragmatic hernia. Semin Fetal Neonatal Med 2022;:101383. [PMID: 35995665 DOI: 10.1016/j.siny.2022.101383] [Reference Citation Analysis]
9 Kishi K, Jarutach J, Ooi YK, Wong NL, Che Mood M, Kandhavello G, Alwi M, Leong MC. High haemoglobin levels at the time of occlusion predict worse outcome for patients with patent ductus arteriosus and pulmonary hypertension. Cardiol Young 2022;:1-8. [PMID: 35950412 DOI: 10.1017/S104795112200244X] [Reference Citation Analysis]
10 Sullivan RT, Handler SS, Feinstein JA, Ogawa M, Liu E, Ma M, Hopper RK, Norris J, Hollander SA, Chen S. Subcutaneous Treprostinil Improves Surgical Candidacy for Next Stage Palliation in Single Ventricle Patients With High-Risk Hemodynamics. Semin Thorac Cardiovasc Surg 2022:S1043-0679(22)00191-5. [PMID: 35931345 DOI: 10.1053/j.semtcvs.2022.07.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Arjaans S, Fries MW, Schoots MH, Schilte CF, Roofthooft MT, Vrijlandt EJ, Bos AF, Kooi EM, Berger RM. Clinical significance of early Pulmonary Hypertension in Preterm Infants. The Journal of Pediatrics 2022. [DOI: 10.1016/j.jpeds.2022.07.039] [Reference Citation Analysis]
12 Osakwe O, Das BB. Successful recovery after blade atrial septostomy in a child with pulmonary hypertensive crisis and cardiac arrest requiring extracorporeal cardiopulmonary resuscitation. Progress in Pediatric Cardiology 2022. [DOI: 10.1016/j.ppedcard.2022.101572] [Reference Citation Analysis]
13 Sankaran D, Lakshminrusimha S. Pulmonary Hypertension in the Newborn- Etiology and Pathogenesis. Seminars in Fetal and Neonatal Medicine 2022. [DOI: 10.1016/j.siny.2022.101381] [Reference Citation Analysis]
14 Yang EL, Levy PT, Critser PJ, Dukhovny D, Evers PD. The Clinical and Cost Utility of Cardiac Catheterizations in Infants with Bronchopulmonary Dysplasia. J Pediatr 2022;246:56-63.e3. [PMID: 35430250 DOI: 10.1016/j.jpeds.2022.04.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Tai C, Hsieh A, Moon-Grady AJ, Keller RL, Teitel D, Nawaytou HM. Pulmonary artery acceleration time in young children is determined by heart rate and transpulmonary gradient but not by pulmonary blood flow: A simultaneous echocardiography-cardiac catheterization study. Echocardiography 2022. [PMID: 35690918 DOI: 10.1111/echo.15397] [Reference Citation Analysis]
16 Ma X, Wang X, Xie L, Lu S, Jiang C, Tang M. The Levels of TNF-α, Tissue Factor, and Coagulation Function in Rats with Pulmonary Hypertension and the Intervention Effect of Sildenafil Encapsulated by Targeted Nanocarriers. Computational and Mathematical Methods in Medicine 2022;2022:1-8. [DOI: 10.1155/2022/8619092] [Reference Citation Analysis]
17 Sallmon H, Koestenberger M, Avian A, Reiterer F, Schwaberger B, Meinel K, Cvirn G, Kurath-Koller S, Gamillscheg A, Hansmann G. Extremely premature infants born at 23-25 weeks gestation are at substantial risk for pulmonary hypertension. J Perinatol 2022. [PMID: 35365772 DOI: 10.1038/s41372-022-01374-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
18 Rudienė V, Kaplerienė L, Jančauskaitė D, Meškėnė E, Palevičiūtė E, Laukytė-slėnienė M, Gasiūnaitė D, Ramašauskaitė D, Jurevičienė E, Gumbienė L. Pregnancy in Congenital Heart Disease, Complicated by Pulmonary Arterial Hypertension—A Challenging Issue for the Pregnant Woman, the Foetus, and Healthcare Professionals. Medicina 2022;58:476. [DOI: 10.3390/medicina58040476] [Reference Citation Analysis]
19 Sun HJ, Wang ZC, Nie XW, Bian JS. Therapeutic potential of carbon monoxide in hypertension-induced vascular smooth muscle cell damage revisited: from physiology and pharmacology. Biochem Pharmacol 2022;:115008. [PMID: 35318039 DOI: 10.1016/j.bcp.2022.115008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Chiu S, Lu C, Lin M, Chen C, Wu M, Wang J. Pulmonary Hypertension in Adult Congenital Heart Disease in Asia: A Distinctive Feature of Complex Congenital Heart Disease. JAHA. [DOI: 10.1161/jaha.121.022596] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Critser PJ, Boyer D, Visner GA, Collins SL, Fynn‐thompson F, Mullen MP. Recovery of right ventricular function after bilateral lung transplantation for pediatric pulmonary hypertension. Pediatric Transplantation. [DOI: 10.1111/petr.14236] [Reference Citation Analysis]
22 Numata R, Takigiku K, Takei K. Clinical impact of subcutaneous treprostinil in trisomy 21 patient with pulmonary arterial hypertension associated with CHD. Cardiol Young 2022;:1-3. [PMID: 35000655 DOI: 10.1017/S1047951121005096] [Reference Citation Analysis]
23 Diekmann F, Legchenko E, Chouvarine P, Lichtinghagen R, Bertram H, Happel CM, Hansmann G. Circulating Interleukin-7 in Human Pulmonary Arterial Hypertension. Front Cardiovasc Med 2021;8:794549. [PMID: 34957265 DOI: 10.3389/fcvm.2021.794549] [Reference Citation Analysis]
24 Hysinger EB, Higano NS, Critser PJ, Woods JC. Imaging in neonatal respiratory disease. Paediatr Respir Rev 2021:S1526-0542(21)00112-3. [PMID: 35074281 DOI: 10.1016/j.prrv.2021.12.002] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
25 Jeremiasen I, Naumburg E, Westöö C, G Weismann C, Tran-Lundmark K. Vasodilator therapy for pulmonary hypertension in children: a national study of patient characteristics and current treatment strategies. Pulm Circ 2021;11:20458940211057891. [PMID: 34925762 DOI: 10.1177/20458940211057891] [Reference Citation Analysis]
26 Issapour A, Frank B, Crook S, Hite MD, Dorn ML, Rosenzweig EB, Ivy DD, Krishnan US. Safety and tolerability of combination therapy with ambrisentan and tadalafil for the treatment of pulmonary arterial hypertension in children: Real-world experience. Pediatr Pulmonol 2021. [PMID: 34921523 DOI: 10.1002/ppul.25796] [Reference Citation Analysis]
27 Schults JA, Charles K, Long D, Erikson S, Brown G, Waak M, Tume L, Hall L, Ullman AJ. Appropriate use criteria for endotracheal suction interventions in mechanically ventilated children: The RAND/UCLA development process. Aust Crit Care 2021:S1036-7314(21)00164-8. [PMID: 34924248 DOI: 10.1016/j.aucc.2021.10.006] [Reference Citation Analysis]
28 Diaz GF, Marquez A, Ruiz-Parra A, Beghetti M, Ivy D. An Acute Hyperoxia Test Predicts Survival in Children with Pulmonary Hypertension Living at High Altitude. High Alt Med Biol 2021;22:395-405. [PMID: 34905397 DOI: 10.1089/ham.2021.0026] [Reference Citation Analysis]
29 Shang Z, Sun J, Hui J, Yu Y, Bian X, Yang B, Deng K, Lin L. Construction of a Support Vector Machine-Based Classifier for Pulmonary Arterial Hypertension Patients. Front Genet 2021;12:781011. [PMID: 34880909 DOI: 10.3389/fgene.2021.781011] [Reference Citation Analysis]
30 Wang T, Duan Y, Liu D, Li G, Liu B. The effect of transglutaminase-2 inhibitor on pulmonary vascular remodeling in rats with pulmonary arterial hypertension. Clin Exp Hypertens 2021;:1-8. [PMID: 34889160 DOI: 10.1080/10641963.2021.2013493] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
31 Wang Y, Li N, Wang Y, Zheng G, An J, Liu C, Wang Y, Liu Q. NF-κB/p65 Competes With Peroxisome Proliferator-Activated Receptor Gamma for Transient Receptor Potential Channel 6 in Hypoxia-Induced Human Pulmonary Arterial Smooth Muscle Cells. Front Cell Dev Biol 2021;9:656625. [DOI: 10.3389/fcell.2021.656625] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
32 Epstein R, Krishnan US. Management of Pulmonary Hypertension in the Pediatric Patient. Cardiol Clin 2022;40:115-27. [PMID: 34809912 DOI: 10.1016/j.ccl.2021.08.010] [Reference Citation Analysis]
33 Taksande A, Pujari D, Jameel PZ, Taksande B, Meshram R. Prevalence of pulmonary hypertension among children with Down syndrome: A systematic review and meta-analysis. World J Clin Pediatr 2021; 10(6): 177-191 [PMID: 34868894 DOI: 10.5409/wjcp.v10.i6.177] [Reference Citation Analysis]
34 Hansmann G, Diekmann F, Chouvarine P, Ius F, Carlens J, Schwerk N, Warnecke G, Vogel-Claussen J, Hohmann D, Alten T, Jack T. Full recovery of right ventricular systolic function in children undergoing bilateral lung transplantation for severe PAH. J Heart Lung Transplant 2021:S1053-2498(21)02568-7. [PMID: 34955331 DOI: 10.1016/j.healun.2021.10.014] [Cited by in Crossref: 5] [Article Influence: 5.0] [Reference Citation Analysis]
35 Fernandes CJ, Calderaro D, Assad APL, Salibe-Filho W, Kato-Morinaga LT, Hoette S, Piloto B, Castro MA, Lisboa RP, Silva TAFD, Martins MA, Alves-Jr JL, Jardim C, Terra-Filho M, Souza R. Update on the Treatment of Pulmonary Arterial Hypertension. Arq Bras Cardiol 2021;117:750-64. [PMID: 34709302 DOI: 10.36660/abc.20200702] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
36 Griffiths M, Yang J, Vaidya D, Nies M, Brandal S, Ivy DD, Hickey F, Wolter-Warmerdam K, Austin ED, Mullen M, Pauciulo MW, Lutz KA, Rosenzweig EB, Hirsch R, Yung D, Nichols WC, Everett AD. Biomarkers of Pulmonary Hypertension Are Altered in Children with Down Syndrome and Pulmonary Hypertension. J Pediatr 2021:S0022-3476(21)01010-6. [PMID: 34687693 DOI: 10.1016/j.jpeds.2021.10.017] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
37 Daly CM, Griffiths M, Simpson CE, Yang J, Damico RL, Vaidya RD, Williams M, Brandal S, Jone PN, Polsen C, Ivy DD, Austin ED, Nichols WC, Pauciulo MW, Lutz K, Nies MK, Rosenzweig EB, Hirsch R, Yung D, Everett AD. Angiostatic Peptide, Endostatin, Predicts Severity in Pediatric Congenital Heart Disease-Associated Pulmonary Hypertension. J Am Heart Assoc 2021;10:e021409. [PMID: 34622662 DOI: 10.1161/JAHA.120.021409] [Reference Citation Analysis]
38 Acosta-Rivera V, Melendez-Montañez JM, Diaz-Sotomayor F, De Jesús-Rojas W. Surfactant Protein C Deficiency in a Puerto Rican Adolescent With a Rare SFTPC Genetic Variant. Cureus 2021;13:e17422. [PMID: 34589332 DOI: 10.7759/cureus.17422] [Reference Citation Analysis]
39 Dufva MJ, Ivy D, Campbell K, Lam A, Rauff A, Breeman KTN, Douwes JM, Berger RMF, Kheyfets VO, Hunter K. Ventricular-vascular coupling is predictive of adverse clinical outcome in paediatric pulmonary arterial hypertension. Open Heart 2021;8:e001611. [PMID: 34583983 DOI: 10.1136/openhrt-2021-001611] [Reference Citation Analysis]
40 García-Aguilar H, Vázquez SG, Trejo KS, Juárez YE, Juárez Vásquez KI, Sarmiento Sánchez ES, Molina HS. Healthcare resource utilization and costs in pediatric pulmonary arterial hypertension in a third-level hospital in Mexico. J Comp Eff Res 2021;10:1251-7. [PMID: 34585624 DOI: 10.2217/cer-2021-0128] [Reference Citation Analysis]
41 Apitz C, Lammers AE. Pediatric pulmonary hypertension. Cardiovasc Diagn Ther 2021;11:1023-7. [PMID: 34527527 DOI: 10.21037/cdt-21-156] [Reference Citation Analysis]
42 Apitz C, Girschick H. Systemic sclerosis-associated pulmonary arterial hypertension in children. Cardiovasc Diagn Ther 2021;11:1137-43. [PMID: 34527539 DOI: 10.21037/cdt-20-901] [Reference Citation Analysis]
43 Lammers AE, Apitz C, Michel-Behnke I, Koestenberger M. A guide to echocardiographic assessment in children and adolescents with pulmonary hypertension. Cardiovasc Diagn Ther 2021;11:1160-77. [PMID: 34527541 DOI: 10.21037/cdt-21-119] [Reference Citation Analysis]
44 Ploegstra MJ, Berger RMF. Prognostic biomarkers in pediatric pulmonary arterial hypertension. Cardiovasc Diagn Ther 2021;11:1089-101. [PMID: 34527535 DOI: 10.21037/cdt-20-374] [Reference Citation Analysis]
45 Lammers AE, Apitz C. Update from the World Symposium on Pulmonary Hypertension 2018: does the new hemodynamic definition of pediatric pulmonary hypertension have an impact on treatment strategies? Cardiovasc Diagn Ther 2021;11:1048-51. [PMID: 34527530 DOI: 10.21037/cdt-20-412] [Reference Citation Analysis]
46 Kaestner M, Apitz C, Lammers AE. Cardiac catheterization in pediatric pulmonary hypertension: a systematic and practical approach. Cardiovasc Diagn Ther 2021;11:1102-10. [PMID: 34527536 DOI: 10.21037/cdt-20-395] [Reference Citation Analysis]
47 Apitz C, Berger RMF, Ivy DD, Humpl T, Bonnet D, Beghetti M, Schranz D, Latus H. Hemodynamic and prognostic impact of the diastolic pulmonary arterial pressure in children with pulmonary arterial hypertension-a registry-based analysis. Cardiovasc Diagn Ther 2021;11:1037-47. [PMID: 34527529 DOI: 10.21037/cdt-20-934] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
48 Gorenflo M, Ziesenitz VC. Treatment of pulmonary arterial hypertension in children. Cardiovasc Diagn Ther 2021;11:1144-59. [PMID: 34527540 DOI: 10.21037/cdt-20-912] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
49 Shmalts AA, Gorbachevsky SV. Evidence base for specific pulmonary vasodilators in adults with congenital heart disease. Terapevticheskii arkhiv 2021;93:1106-16. [DOI: 10.26442/00403660.2021.09.201022] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
50 Sweatt AJ, Reddy R, Rahaghi FN, Al-Naamani N; American Thoracic Society Pulmonary Circulation Assembly Early Career Working Group. What's new in pulmonary hypertension clinical research: lessons from the best abstracts at the 2020 American Thoracic Society International Conference. Pulm Circ 2021;11:20458940211040713. [PMID: 34471517 DOI: 10.1177/20458940211040713] [Reference Citation Analysis]
51 Miura M, Imai K, Tsuda H, Miki R, Tano S, Ito Y, Hirako-Takamura S, Moriyama Y, Ushida T, Iitani Y, Nakano-Kobayashi T, Toyokuni S, Kajiyama H, Kotani T. Prenatal Molecular Hydrogen Administration Ameliorates Several Findings in Nitrofen-Induced Congenital Diaphragmatic Hernia. Int J Mol Sci 2021;22:9500. [PMID: 34502408 DOI: 10.3390/ijms22179500] [Reference Citation Analysis]
52 Morales-Demori R, Mallory GB, Chartan C, Coleman R, Ruiz F, Villafranco N, Whalen E, Varghese N. Outcomes of COVID-19 infection in pediatric pulmonary hypertension: A single-center experience. Pediatr Pulmonol 2021;56:3960-5. [PMID: 34460150 DOI: 10.1002/ppul.25650] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
53 Leard LE, Holm AM, Valapour M, Glanville AR, Attawar S, Aversa M, Campos SV, Christon LM, Cypel M, Dellgren G, Hartwig MG, Kapnadak SG, Kolaitis NA, Kotloff RM, Patterson CM, Shlobin OA, Smith PJ, Solé A, Solomon M, Weill D, Wijsenbeek MS, Willemse BWM, Arcasoy SM, Ramos KJ. Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2021;40:1349-79. [PMID: 34419372 DOI: 10.1016/j.healun.2021.07.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 37] [Article Influence: 6.0] [Reference Citation Analysis]
54 Critser PJ, Evers PD, Schneider K, Hirsch R, Taylor MD, Woods JC, Lang SM. Echocardiography-derived septal curvature correlated with invasive hemodynamics in pediatric pulmonary hypertension. J Echocardiogr 2021. [PMID: 34415551 DOI: 10.1007/s12574-021-00545-6] [Reference Citation Analysis]
55 Diekmann F, Chouvarine P, Sallmon H, Meyer-Kobbe L, Kieslich M, Plouffe BD, Murthy SK, Lichtinghagen R, Legchenko E, Hansmann G. Soluble Receptor for Advanced Glycation End Products (sRAGE) Is a Sensitive Biomarker in Human Pulmonary Arterial Hypertension. Int J Mol Sci 2021;22:8591. [PMID: 34445297 DOI: 10.3390/ijms22168591] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
56 Varghese NP, Tillman RH, Keller RL. Pulmonary hypertension is an important co-morbidity in developmental lung diseases of infancy: Bronchopulmonary dysplasia and congenital diaphragmatic hernia. Pediatr Pulmonol 2021;56:670-7. [PMID: 33561308 DOI: 10.1002/ppul.25258] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
57 Malloy KW, Austin ED. Pulmonary hypertension in the child with bronchopulmonary dysplasia. Pediatr Pulmonol 2021. [PMID: 34324276 DOI: 10.1002/ppul.25602] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
58 Arvanitaki A, Januszewska K, Malec E, Baumgartner H, Kehl HG, Lammers AE. Against all odds-late repair of multiple shunt lesions in a patient with Down syndrome: a case report. Eur Heart J Case Rep 2021;5:ytab234. [PMID: 34377902 DOI: 10.1093/ehjcr/ytab234] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
59 Bajolle F, Malekzadeh-Milani S, Lévy M, Bonnet D. Multifactorial origin of pulmonary hypertension in a child with congenital heart disease, Down syndrome, and BMPR-2 mutation. Pulm Circ 2021;11:20458940211027433. [PMID: 34285797 DOI: 10.1177/20458940211027433] [Reference Citation Analysis]
60 Mukherjee D, Konduri GG. Pediatric Pulmonary Hypertension: Definitions, Mechanisms, Diagnosis, and Treatment. Compr Physiol 2021;11:2135-90. [PMID: 34190343 DOI: 10.1002/cphy.c200023] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
61 Colglazier E, Ng AJ, Parker C, Nawaytou H, Fineman JR. Safety and Tolerability of a Rapid Transition From Intravenous Treprostinil to Oral Selexipag in Three Adolescent Patients With Pulmonary Arterial Hypertension. J Pediatr Pharmacol Ther 2021;26:512-6. [PMID: 34239406 DOI: 10.5863/1551-6776-26.5.512] [Reference Citation Analysis]
62 Douwes JM, Zijlstra WM, Rosenzweig EB, Ploegstra MJ, Krishnan US, Haarman MG, Roofthooft MTR, Postmus D, Hillege HL, Ivy DD, Berger RMF. Parenteral Prostanoids in Pediatric Pulmonary Arterial Hypertension: Start Early, Dose High, Combine. Ann Am Thorac Soc 2021. [PMID: 34181866 DOI: 10.1513/AnnalsATS.202012-1563OC] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
63 Ivy D, Bonnet D, Berger R, Meyer GMB, Baygani S, Li B; LVHV Study Group. Efficacy and safety of tadalafil in a pediatric population with pulmonary arterial hypertension: phase 3 randomized, double-blind placebo-controlled study. Pulm Circ 2021;11:20458940211024955. [PMID: 34234945 DOI: 10.1177/20458940211024955] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
64 Beghetti M, Berger RMF, Bonnet D, Grill S, Lesage C, Lemarie JC, Ivy DD. Echocardiographic Changes and Long-Term Clinical Outcomes in Pediatric Patients With Pulmonary Arterial Hypertension Treated With Bosentan for 72 Weeks: A Post-hoc Analysis From the FUTURE 3 Study. Front Pediatr 2021;9:681538. [PMID: 34222150 DOI: 10.3389/fped.2021.681538] [Reference Citation Analysis]
65 Fortas F, Di Nardo M, Yousef N, Humbert M, De Luca D. Life-threatening PPHN refractory to nitric oxide: proposal for a rational therapeutic algorithm. Eur J Pediatr 2021;180:2379-87. [PMID: 34091748 DOI: 10.1007/s00431-021-04138-4] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
66 Allali S, Taylor M, Brice J, Montalembert M. Chronic organ injuries in children with sickle cell disease. Haematologica 2021;106:1535-44. [PMID: 33626864 DOI: 10.3324/haematol.2020.271353] [Reference Citation Analysis]
67 Zhao Y, Liang L, Liu G, Zheng H, Dai L, Wang Y, Wang L, Sheng W. Asphyxia and Neonatal Respiratory Distress Syndrome Are Independent Predictors of the Non-response to Inhaled Nitric Oxide in the Newborns With PPHN. Front Pediatr 2021;9:665830. [PMID: 34095030 DOI: 10.3389/fped.2021.665830] [Reference Citation Analysis]
68 Hansmann G, Christou H, Koestenberger M, Sallmon H. Off-label use of PAH-targeted medications approved for adults and their financial coverage by health insurances are vital for children with pulmonary hypertension. Eur J Clin Invest 2021;51:e13571. [PMID: 33834481 DOI: 10.1111/eci.13571] [Reference Citation Analysis]
69 Ivy D, Frank BS. Update on pediatric pulmonary arterial hypertension. Curr Opin Cardiol 2021;36:67-79. [PMID: 33136663 DOI: 10.1097/HCO.0000000000000822] [Reference Citation Analysis]
70 Shu T, Chen H, Wang L, Wang W, Feng P, Xiang R, Wen L, Huang W. The Efficacy and Safety of Pulmonary Vasodilators in Pediatric Pulmonary Hypertension (PH): A Systematic Review and Meta-analysis. Front Pharmacol 2021;12:668902. [PMID: 33967811 DOI: 10.3389/fphar.2021.668902] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
71 Luo L, Wu J, Lin T, Lian G, Wang H, Gao G, Xie L. Influence of atorvastatin on metabolic pattern of rats with pulmonary hypertension. Aging (Albany NY) 2021;13:11954-68. [PMID: 33886502 DOI: 10.18632/aging.202898] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
72 Arafuri N, Murni IK, Idris NS, Uiterwaal CSPM, Savitri AI, Nugroho S, Noormanto N. Survival of Left-to-Right Shunt Repair in Children with Pulmonary Arterial Hypertension at a Tertiary Hospital in a Low-to-Middle-Income Country. Glob Heart 2021;16:25. [PMID: 34040938 DOI: 10.5334/gh.831] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
73 Cramer J, Bevry M, Handler S, Tillman K, Abourashed EA. Stability Determination of an Extemporaneously Compounded Ambrisentan Suspension by High Performance Liquid Chromatography Analysis. J Pediatr Pharmacol Ther 2021;26:265-70. [PMID: 33833628 DOI: 10.5863/1551-6776-26.3.265] [Reference Citation Analysis]
74 Gaheen R, El Amrousy D, Hodeib H, Elnemr S. Plasma copeptin levels in children with pulmonary arterial hypertension associated with congenital heart disease. Eur J Pediatr 2021;180:2889-95. [DOI: 10.1007/s00431-021-04060-9] [Reference Citation Analysis]
75 Gaheen R, El Amrousy D, Hodeib H, Elnemr S. Plasma copeptin levels in children with pulmonary arterial hypertension associated with congenital heart disease. Eur J Pediatr 2021;180:2889-95. [PMID: 33813676 DOI: 10.1007/s00431-021-04060-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
76 Khirfan G, Li M, Wang X, Dweik RA, Heresi GA, Tonelli AR. Is pulmonary vascular resistance index better than pulmonary vascular resistance in predicting outcomes in pulmonary arterial hypertension? J Heart Lung Transplant 2021;40:614-22. [PMID: 33962868 DOI: 10.1016/j.healun.2021.03.022] [Reference Citation Analysis]
77 Rosenzweig EB, Ankola A, Krishnan U, Middlesworth W, Bacha E, Bacchetta M. A novel unidirectional-valved shunt approach for end-stage pulmonary arterial hypertension: Early experience in adolescents and adults. The Journal of Thoracic and Cardiovascular Surgery 2021;161:1438-1446.e2. [DOI: 10.1016/j.jtcvs.2019.10.149] [Cited by in Crossref: 13] [Cited by in F6Publishing: 19] [Article Influence: 13.0] [Reference Citation Analysis]
78 Tamimi O, Mohammed MHA. Pulmonary Vascular Resistance Measurement Remains Keystone in Congenital Heart Disease Management. Front Cardiovasc Med 2021;8:607104. [PMID: 33869298 DOI: 10.3389/fcvm.2021.607104] [Reference Citation Analysis]
79 Juaneda E, Catalfamo D, Fregapani JP, Peirone A, Juaneda I, Kreutzer C, Lucino S. Magnetic resonance lymphangiography in group 1 paediatric pulmonary arterial hypertension. Pulm Circ 2021;11:20458940211004777. [PMID: 33868641 DOI: 10.1177/20458940211004777] [Reference Citation Analysis]
80 Lafuente-Romero A, Rodriguez Ogando A. Selexipag use for paediatric pulmonary hypertension: a single centre report focussed on congenital heart disease patients. Cardiol Young 2021;:1-3. [PMID: 33781364 DOI: 10.1017/S1047951121000937] [Reference Citation Analysis]
81 Al-Qadi M, LeVarge B, Ford HJ. Epidemiology, Pathogenesis, and Clinical Approach in Group 5 Pulmonary Hypertension. Front Med (Lausanne) 2020;7:616720. [PMID: 33842491 DOI: 10.3389/fmed.2020.616720] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
82 Almeida-Jones M, Nawathe P, Markush D, Garg R. Atypical Causes of Severe Pulmonary Hypertension in Infancy. Glob Pediatr Health 2021;8:2333794X211001240. [PMID: 33816711 DOI: 10.1177/2333794X211001240] [Reference Citation Analysis]
83 Dasgupta S, Richardson JC, Aly AM, Jain SK. Role of functional echocardiographic parameters in the diagnosis of bronchopulmonary dysplasia-associated pulmonary hypertension. J Perinatol 2021. [PMID: 33686118 DOI: 10.1038/s41372-021-01009-6] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
84 Dasgupta S, Bettermann E, Kelleman M, Kanaan U, Sachdeva R, Petit C, Kim D, Vincent R, Bauser-Heaton H. N-terminal pro-B-type-natriuretic peptide as a screening tool for pulmonary hypertension in the paediatric population. Cardiol Young 2021;:1-13. [PMID: 33650482 DOI: 10.1017/S1047951121000585] [Reference Citation Analysis]
85 Seabrook RB, Grover TR, Rintoul N, Weems M, Keene S, Brozanski B, DiGeronimo R, Haberman B, Hedrick H, Gien J, Ali N, Chapman R, Daniel J, Harrison HA, Johnson Y, Porta NFM, Uhing M, Zaniletti I, Murthy K; Children’s Hospitals Neonatal Consortium Congenital Diaphragmatic Hernia Focus Group. Treatment of pulmonary hypertension during initial hospitalization in a multicenter cohort of infants with congenital diaphragmatic hernia (CDH). J Perinatol 2021;41:803-13. [PMID: 33649432 DOI: 10.1038/s41372-021-00923-z] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
86 Wadia RS, Bernier ML, Diaz-Rodriguez NM, Goswami DK, Nyhan SM, Steppan J. Update on Perioperative Pediatric Pulmonary Hypertension Management. J Cardiothorac Vasc Anesth 2021:S1053-0770(21)00190-7. [PMID: 33781669 DOI: 10.1053/j.jvca.2021.02.055] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
87 Ablonczy L, Ferenci T, Somoskövi O, Osváth R, Reusz GS, Kis E. Prognostic Value of Early Risk Stratification in Pediatric Pulmonary Arterial Hypertension. Transplant Proc 2021;53:1439-42. [PMID: 33622612 DOI: 10.1016/j.transproceed.2021.01.047] [Reference Citation Analysis]
88 Mallory GB, Abman SH. The many challenges to the field of pediatric pulmonology posed by pediatric pulmonary hypertension and the path forward. Pediatr Pulmonol 2021;56:583-6. [PMID: 33561305 DOI: 10.1002/ppul.25238] [Reference Citation Analysis]
89 Nawaytou H, Fineman JR, Moledina S, Ivy D, Abman SH, Cerro MJD. Practice patterns of pulmonary hypertension secondary to left heart disease among pediatric pulmonary hypertension providers. Pulm Circ 2021;11:2045894021991446. [PMID: 33623667 DOI: 10.1177/2045894021991446] [Reference Citation Analysis]
90 Haarman MG, Kerstjens-Frederikse WS, Berger RMF. TBX4 variants and pulmonary diseases: getting out of the 'Box'. Curr Opin Pulm Med 2020;26:277-84. [PMID: 32195678 DOI: 10.1097/MCP.0000000000000678] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
91 Arjaans S, Zwart EAH, Roofthooft M, Kooi EMW, Bos AF, Berger RMF. Pulmonary hypertension in extremely preterm infants: a call to standardize echocardiographic screening and follow-up policy. Eur J Pediatr 2021;180:1855-65. [PMID: 33528615 DOI: 10.1007/s00431-021-03931-5] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
92 Albinni S, Pavo I, Kitzmueller E, Michel-Behnke I. Macitentan in infants and children with pulmonary hypertensive vascular disease. Feasibility, tolerability and practical issues - a single-centre experience. Pulm Circ 2021;11:2045894020979503. [PMID: 33532055 DOI: 10.1177/2045894020979503] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
93 Rosenzweig EB, Krishnan U. Congenital Heart Disease-Associated Pulmonary Hypertension. Clin Chest Med 2021;42:9-18. [PMID: 33541620 DOI: 10.1016/j.ccm.2020.11.005] [Reference Citation Analysis]
94 Frank BS, Schäfer M, Thomas TM, Ivy DD, Jone PN. Longitudinal assessment of right atrial conduit fraction provides additional insight to predict adverse events in pediatric pulmonary hypertension. Int J Cardiol 2021;329:242-5. [PMID: 33400972 DOI: 10.1016/j.ijcard.2020.12.073] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
95 Meinel K, Koestenberger M, Sallmon H, Hansmann G, Pieles GE. Echocardiography for the Assessment of Pulmonary Hypertension and Congenital Heart Disease in the Young. Diagnostics (Basel) 2020;11:E49. [PMID: 33396225 DOI: 10.3390/diagnostics11010049] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
96 Hasan B, Hansmann G, Budts W, Heath A, Hoodbhoy Z, Jing ZC, Koestenberger M, Meinel K, Mocumbi AO, Radchenko GD, Sallmon H, Sliwa K, Kumar RK; European Pediatric Pulmonary Vascular Disease Network (EPPVDN), endorsed by AEPC, CSC, PASCAR, PCS, and PCSI. Challenges and Special Aspects of Pulmonary Hypertension in Middle- to Low-Income Regions: JACC State-of-the-Art Review. J Am Coll Cardiol 2020;75:2463-77. [PMID: 32408981 DOI: 10.1016/j.jacc.2020.03.047] [Cited by in Crossref: 2] [Cited by in F6Publishing: 15] [Article Influence: 1.0] [Reference Citation Analysis]
97 Bobhate P, Garg S, Sharma A, Roy D, Raut A, Pawar R, Karande T, Kulkarni S. Congenital extrahepatic portocaval malformation: Rare but potentially treatable cause of pulmonary hypertension. Indian Heart J 2021;73:99-103. [PMID: 33714417 DOI: 10.1016/j.ihj.2020.12.015] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
98 Ramphul M, Gallagher K, Warrier K, Jagani S, Bhatt JM. Why is a paediatric respiratory specialist integral to the paediatric rheumatology clinic? Breathe (Sheff) 2020;16:200212. [PMID: 33447294 DOI: 10.1183/20734735.0212-2020] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
99 Baczynski M, Kelly E, McNamara PJ, Shah PS, Jain A. Short and long-term outcomes of chronic pulmonary hypertension in preterm infants managed using a standardized algorithm. Pediatr Pulmonol 2021;56:1155-64. [PMID: 33270376 DOI: 10.1002/ppul.25200] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
100 Doi H, Muneuchi J, Watanabe M, Sugitani Y, Matsuoka R, Ezaki H, Ochiai Y. Characteristics of the pulmonary circulation in infants with complete atrioventricular septal defect. Cardiol Young 2021;31:556-61. [PMID: 33303047 DOI: 10.1017/S1047951120004424] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
101 Alakhfash AA, Alqwaiee A, Alakhfash GA, Alhajjaj A, Almesned AA. Pulmonary hypertension associated with congenital heart disease; clinical decision scenario. Respir Med Case Rep 2020;31:101286. [PMID: 33294357 DOI: 10.1016/j.rmcr.2020.101286] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
102 Critser PJ, Evers PD, McGovern E, Cash M, Hirsch R. Balloon atrial septostomy as initial therapy in pediatric pulmonary hypertension. Pulm Circ 2020;10:2045894020958970. [PMID: 33282186 DOI: 10.1177/2045894020958970] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
103 Wang L, Liu J, Zhong Y, Zhang M, Xiong J, Shen J, Tong Z, Xu Z. Medical Image-Based Hemodynamic Analyses in a Study of the Pulmonary Artery in Children With Pulmonary Hypertension Related to Congenital Heart Disease. Front Pediatr 2020;8:521936. [PMID: 33344379 DOI: 10.3389/fped.2020.521936] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
104 Joye R, Lador F, Aggoun Y, Farhat N, Wacker J, Wildhaber BE, Vallée JP, Hachulla AL, McLin VA, Beghetti M. Outcome of paediatric portopulmonary hypertension in the modern management era: A case report of 6 patients. J Hepatol 2021;74:742-7. [PMID: 33276028 DOI: 10.1016/j.jhep.2020.11.039] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
105 Chen JY, Griffiths M, Yang J, Nies MK, Damico RL, Simpson CE, Vaidya RD, Brandal S, Ivy DD, Austin ED, Nichols WC, Pauciulo MW, Lutz K, Rosenzweig EB, Hirsch R, Yung D, Everett AD. Elevated Interleukin-6 Levels Predict Clinical Worsening in Pediatric Pulmonary Arterial Hypertension. J Pediatr 2020;223:164-169.e1. [PMID: 32711743 DOI: 10.1016/j.jpeds.2020.04.041] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
106 Migdał A, Żuk M, Jagiełłowicz-Kowalska D, Powichrowska Z, Brzezińska-Rajszys G. Which Functional Classification Scale is Optimal for Children with Pulmonary Hypertension (PAH)? Pediatr Cardiol 2020;41:1725-9. [PMID: 32772124 DOI: 10.1007/s00246-020-02434-8] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
107 Capel A, Lévy M, Szezepanski I, Malekzadeh-Milani S, Vouhé P, Bonnet D. Potts anastomosis in children with severe pulmonary arterial hypertension and atrial septal defect. ESC Heart Fail 2021;8:326-32. [PMID: 33216469 DOI: 10.1002/ehf2.13074] [Reference Citation Analysis]
108 Maltret A, Morel N, Levy M, Evangelista M, Malekzadeh-Milani S, Barbet P, Costedoat-Chalumeau N, Bonnet D. Pulmonary hypertension associated with congenital heart block and neonatal lupus syndrome: A series of four cases. Lupus 2021;30:307-14. [PMID: 33198562 DOI: 10.1177/0961203320973073] [Reference Citation Analysis]
109 Deng X, Li S, Qiu Q, Jin B, Yan M, Hu Y, Wu Y, Zhou H, Zhang G, Zheng X. Where the congenital heart disease meets the pulmonary arterial hypertension, FLNA matters: a case report and literature review. BMC Pediatr 2020;20:504. [PMID: 33143682 DOI: 10.1186/s12887-020-02393-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
110 Zhang Q, Xu B, Lv J, Wang Z, Du J. Safety and effect of sildenafil on treating paediatric pulmonary arterial hypertension: a meta-analysis on the randomised controlled trials. Cardiol Young 2020;30:1882-9. [DOI: 10.1017/s104795112000311x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
111 Welch CL, Chung WK. Genetics and Genomics of Pediatric Pulmonary Arterial Hypertension. Genes (Basel) 2020;11:E1213. [PMID: 33081265 DOI: 10.3390/genes11101213] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
112 Chiu SN, Weng KP, Lin MC, Wang JN, Hwang BT, Dai ZK, Lin SM, Chang JS, Lin IC, Wu MH, Lu CW, Lin MT, Chen CA, Hua YC, Wu JM, Wang JK; TACHYON investigators. Congenital heart disease with pulmonary artery hypertension in an Asian cohort-initial report from TACHYON (TAiwan congenital heart disease associated with pulmonarY arterial hypertension) registry. Int J Cardiol 2020;317:49-55. [PMID: 32522677 DOI: 10.1016/j.ijcard.2020.05.086] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
113 Kam CW, Ruiz FE. Opportunities and challenges of pharmacotherapy for pulmonary arterial hypertension in children. Pediatr Pulmonol 2021;56:593-613. [PMID: 33002306 DOI: 10.1002/ppul.25101] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
114 Truong U, Meinel K, Haddad F, Koestenberger M, Carlsen J, Ivy D, Jone PN. Update on noninvasive imaging of right ventricle dysfunction in pulmonary hypertension. Cardiovasc Diagn Ther 2020;10:1604-24. [PMID: 33224776 DOI: 10.21037/cdt-20-272] [Cited by in Crossref: 2] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
115 Schweintzger S, Koestenberger M, Schlagenhauf A, Grangl G, Burmas A, Kurath-Koller S, Pocivalnik M, Sallmon H, Baumgartner D, Hansmann G, Gamillscheg A. Safety and efficacy of the endothelin receptor antagonist macitentan in pediatric pulmonary hypertension. Cardiovasc Diagn Ther 2020;10:1675-85. [PMID: 33224780 DOI: 10.21037/cdt.2020.04.01] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
116 Frank BS, Ivy DD. Pediatric Pulmonary Arterial Hypertension. Pediatric Clinics of North America 2020;67:903-21. [DOI: 10.1016/j.pcl.2020.06.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
117 Koestenberger M, Bogaard HJ, Hansmann G. Getting to the bottom of right heart failure. Cardiovasc Diagn Ther 2020;10:1517-21. [PMID: 33224771 DOI: 10.21037/cdt-20-565] [Reference Citation Analysis]
118 Hansmann G, Rich S, Maron BA. Cardiac catheterization in pulmonary hypertension: doing it right, with a catheter on the left. Cardiovasc Diagn Ther 2020;10:1718-24. [PMID: 33224785 DOI: 10.21037/cdt-20-483] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
119 Guslits E, Steurer MA, Nawaytou H, Keller RL. Longitudinal B-Type Natriuretic Peptide Levels Predict Outcome in Infants with Congenital Diaphragmatic Hernia. J Pediatr 2021;229:191-198.e2. [PMID: 32997999 DOI: 10.1016/j.jpeds.2020.09.064] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
120 Bravo-Valenzuela NJM, Navarro F, Silva SP. Use of selexipag in a teenage patient with pulmonary arterial hypertension. Ann Pediatr Cardiol 2021;14:75-8. [PMID: 33679065 DOI: 10.4103/apc.APC_63_19] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
121 Mirabile C, Malekzadeh-Milani S, Bojan M, Raisky O, Gaudin R, Bonnet D, Boudjemline Y. A case series of transcatheter Potts Shunt creation in a pediatric population affected with refractory pulmonary artery hypertension: focus on the role of ECMO. Perfusion 2021;36:415-20. [PMID: 32880213 DOI: 10.1177/0267659120954169] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
122 Sastry UMK, M J, Kumar RK, Ghosh S, A P B, Subramanian A, Managuli A, Gangadhara M, Manjunath CN. Thiamine-responsive acute severe pulmonary hypertension in exclusively breastfeeding infants: a prospective observational study. Arch Dis Child 2021;106:241-6. [DOI: 10.1136/archdischild-2019-318777] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
123 Ruoss JL, Rios DR, Levy PT. Updates on Management for Acute and Chronic Phenotypes of Neonatal Pulmonary Hypertension. Clinics in Perinatology 2020;47:593-615. [DOI: 10.1016/j.clp.2020.05.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
124 Panagiotidou E, Boutou A, Pitsiou G. An evaluation of selexipag for the treatment of pulmonary hypertension. Expert Opin Pharmacother 2021;22:29-36. [PMID: 32867545 DOI: 10.1080/14656566.2020.1812579] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
125 Haarman MG, Lévy M, Roofthooft MT, Douwes JM, Vissia-kazemier TR, Szezepanski I, Berger RM, Bonnet D. Upfront triple combination therapy in severe paediatric pulmonary arterial hypertension. Eur Respir J 2021;57:2001120. [DOI: 10.1183/13993003.01120-2020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
126 Albinni S, Marx M, Lang IM. Focused Update on Pulmonary Hypertension in Children-Selected Topics of Interest for the Adult Cardiologist. Medicina (Kaunas) 2020;56:E420. [PMID: 32825190 DOI: 10.3390/medicina56090420] [Reference Citation Analysis]
127 Beshay S, Sahay S, Humbert M. Evaluation and management of pulmonary arterial hypertension. Respir Med 2020;171:106099. [PMID: 32829182 DOI: 10.1016/j.rmed.2020.106099] [Cited by in Crossref: 1] [Cited by in F6Publishing: 13] [Article Influence: 0.5] [Reference Citation Analysis]
128 Chao CM, Chong L, Chu X, Shrestha A, Behnke J, Ehrhardt H, Zhang J, Chen C, Bellusci S. Targeting Bronchopulmonary Dysplasia-Associated Pulmonary Hypertension (BPD-PH): Potential Role of the FGF Signaling Pathway in the Development of the Pulmonary Vascular System. Cells 2020;9:E1875. [PMID: 32796770 DOI: 10.3390/cells9081875] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
129 Garekar S, Meeran T, Dhake S, Malankar D. Valved reverse Potts shunt in a case of pulmonary hypertension due to pulmonary veno-occlusive disease. Indian J Thorac Cardiovasc Surg 2021;37:89-92. [PMID: 33442212 DOI: 10.1007/s12055-020-00993-2] [Reference Citation Analysis]
130 Constantine A, Dimopoulos K, Opotowsky AR. Congenital Heart Disease and Pulmonary Hypertension. Cardiology Clinics 2020;38:445-56. [DOI: 10.1016/j.ccl.2020.04.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
131 Frank BS, Schafer M, Thomas TM, Haxel C, Ivy DD, Jone P. Right Atrial Conduit Phase Emptying Predicts Risk of Adverse Events in Pediatric Pulmonary Arterial Hypertension. Journal of the American Society of Echocardiography 2020;33:1006-13. [DOI: 10.1016/j.echo.2020.02.015] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
132 Jeremiasen I, Tran-Lundmark K, Idris N, Tran PK, Moledina S. Pulmonary Vasodilator Therapy in Children with Single Ventricle Physiology: Effects on Saturation and Pulmonary Arterial Pressure. Pediatr Cardiol 2020;41:1651-9. [PMID: 32734529 DOI: 10.1007/s00246-020-02424-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
133 Hayashi T, Ono H, Kaneko Y. Association of Preoperative Mixed Venous Oxygen Saturation with Postoperative Segmental Pulmonary Hypertension in Pulmonary Atresia with Ventricular Septal Defect and Major Aortopulmonary Collaterals. Pediatr Cardiol 2020;41:1689-96. [PMID: 32710283 DOI: 10.1007/s00246-020-02428-6] [Reference Citation Analysis]
134 Wiltshire E, Peña AS, MacKenzie K, Shaw G, Couper J. High dose folic acid is a potential treatment for pulmonary hypertension, including when associated with COVID-19 pneumonia. Med Hypotheses 2020;143:110142. [PMID: 32759013 DOI: 10.1016/j.mehy.2020.110142] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
135 Martinho S, Adão R, Leite-Moreira AF, Brás-Silva C. Persistent Pulmonary Hypertension of the Newborn: Pathophysiological Mechanisms and Novel Therapeutic Approaches. Front Pediatr 2020;8:342. [PMID: 32850518 DOI: 10.3389/fped.2020.00342] [Cited by in Crossref: 7] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
136 Souza MFS, Carvalho ES, Maeda NY, Thomaz AM, Zorzanelli L, Castro CR, Pereira J, Lopes AA. Macrophage migration inhibitory factor and chemokine RANTES in young pediatric patients with congenital cardiac communications: Relation to hemodynamic parameters and the presence of Down syndrome. Cytokine 2020;134:155192. [PMID: 32683105 DOI: 10.1016/j.cyto.2020.155192] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
137 Vazquez ZGS, Klinger JR. Guidelines for the Treatment of Pulmonary Arterial Hypertension. Lung 2020;198:581-96. [PMID: 32671468 DOI: 10.1007/s00408-020-00375-w] [Cited by in Crossref: 6] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
138 Avitabile CM, Vorhies EE, Ivy DD. Drug Treatment of Pulmonary Hypertension in Children. Paediatr Drugs 2020;22:123-47. [PMID: 31960361 DOI: 10.1007/s40272-019-00374-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
139 Arjaans S, Haarman MG, Roofthooft MTR, Fries MWF, Kooi EMW, Bos AF, Berger RMF. Fate of pulmonary hypertension associated with bronchopulmonary dysplasia beyond 36 weeks postmenstrual age. Arch Dis Child Fetal Neonatal Ed 2021;106:45-50. [PMID: 32571832 DOI: 10.1136/archdischild-2019-318531] [Cited by in Crossref: 9] [Cited by in F6Publishing: 14] [Article Influence: 4.5] [Reference Citation Analysis]
140 Sehgal A, Steenhorst JJ, Mclennan DI, Merkus D, Ivy D, McNamara PJ. The Left Heart, Systemic Circulation, and Bronchopulmonary Dysplasia: Relevance to Pathophysiology and Therapeutics. J Pediatr 2020;225:13-22.e2. [PMID: 32553872 DOI: 10.1016/j.jpeds.2020.06.031] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
141 Coleman RD, Chartan CA, Ivy DD. MicroRNA as a Biomarker in Pediatric Pulmonary Hypertension: A Step Closer to the Holy Grail? Pediatr Crit Care Med 2020;21:393-4. [PMID: 32251186 DOI: 10.1097/PCC.0000000000002219] [Reference Citation Analysis]
142 Hansmann G, Sallmon H, Roehr CC, Kourembanas S, Austin ED, Koestenberger M; European Pediatric Pulmonary Vascular Disease Network (EPPVDN). Pulmonary hypertension in bronchopulmonary dysplasia. Pediatr Res 2021;89:446-55. [PMID: 32521539 DOI: 10.1038/s41390-020-0993-4] [Cited by in Crossref: 15] [Cited by in F6Publishing: 29] [Article Influence: 7.5] [Reference Citation Analysis]
143 Kwiatkowska J, Zuk M, Migdal A, Kusa J, Skiba E, Zygielo K, Przetocka K, Werynski P, Banaszak P, Rzeznik-Bieniaszewska A, Surmacz R, Bobkowski W, Wojcicka-Urbanska B, Werner B, Pluzanska J, Ostrowska K, Waldoch A, Kopec G. Children and Adolescents with Pulmonary Arterial Hypertension: Baseline and Follow-Up Data from the Polish Registry of Pulmonary Hypertension (BNP-PL). J Clin Med 2020;9:E1717. [PMID: 32503164 DOI: 10.3390/jcm9061717] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
144 Haarman MG, Kerstjens-Frederikse WS, Vissia-Kazemier TR, Breeman KTN, Timens W, Vos YJ, Roofthooft MTR, Hillege HL, Berger RMF. The Genetic Epidemiology of Pediatric Pulmonary Arterial Hypertension. J Pediatr 2020;225:65-73.e5. [PMID: 32502478 DOI: 10.1016/j.jpeds.2020.05.051] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
145 Burkett DA, Patel SS, Mertens L, Friedberg MK, Ivy DD. Relationship Between Left Ventricular Geometry and Invasive Hemodynamics in Pediatric Pulmonary Hypertension. Circ Cardiovasc Imaging 2020;13:e009825. [PMID: 32408829 DOI: 10.1161/CIRCIMAGING.119.009825] [Cited by in Crossref: 8] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
146 Aye CYL, Lewandowski AJ, Lamata P, Upton R, Davis E, Ohuma EO, Kenworthy Y, Boardman H, Frost AL, Adwani S, McCormick K, Leeson P. Prenatal and Postnatal Cardiac Development in Offspring of Hypertensive Pregnancies. J Am Heart Assoc 2020;9:e014586. [PMID: 32349586 DOI: 10.1161/JAHA.119.014586] [Cited by in Crossref: 6] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
147 Saito R, Kasajima A, Kawabata Y, Miki Y, Tominaga J, Tatebe S, Nakajima H, Hata S, Inoue C, Taniuchi S, Fujishima F, Watanabe M, Sato Y, Okada Y, Sasano H. Vasohibin-1 and miR-720 expression in diffuse pulmonary capillary hemangiomatosis-like changes associated with pulmonary hypoplasia. Pathol Int 2020;70:470-2. [PMID: 32314456 DOI: 10.1111/pin.12931] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
148 Koestenberger M, Avian A, Cantinotti M, Meinel K, Hansmann G. A novel echocardiographic approach indicates disease severity in pediatric pulmonary hypertension. Pediatr Int 2020;62:637-9. [PMID: 32304149 DOI: 10.1111/ped.14163] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
149 AlSalman F, Howlett M, Breatnach C, Kelly H, O'Brien F. Supporting the use of sildenafil infusions in paediatric and neonatal intensive care - A compatibility study. Eur J Pharm Biopharm 2020;151:153-61. [PMID: 32289494 DOI: 10.1016/j.ejpb.2020.04.008] [Reference Citation Analysis]
150 Angelini A, di Gioia C, Doran H, Fedrigo M, Henriques de Gouveia R, Ho SY, Leone O, Sheppard MN, Thiene G, Dimopoulos K, Mulder B, Padalino M, van der Wal AC; Association for European Cardiovascular Pathology (AECVP). Autopsy in adults with congenital heart disease (ACHD). Virchows Arch 2020;476:797-820. [PMID: 32266476 DOI: 10.1007/s00428-020-02779-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
151 Smith AM, Levy PT, Franklin O, Molloy E, El-khuffash A. Pulmonary hypertension and myocardial function in infants and children with Down syndrome. Arch Dis Child 2020;105:1031-4. [DOI: 10.1136/archdischild-2019-318178] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
152 Álvarez‐fuente M, Garrido‐lestache E, Rivero N, Centella T, Lamas MJ, Pérez‐caballero C, Vázquez JL, Del Cerro MJ. Implantable LENUS pro pump for treprostinil infusion in three pediatric patients. Pediatr Pulmonol 2020;55:1254-8. [DOI: 10.1002/ppul.24707] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
153 Nawaytou H, Steurer MA, Zhao Y, Guslits E, Teitel D, Fineman JR, Keller RL. Clinical Utility of Echocardiography in Former Preterm Infants with Bronchopulmonary Dysplasia. Journal of the American Society of Echocardiography 2020;33:378-388.e1. [DOI: 10.1016/j.echo.2019.10.012] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
154 Popescu MR, Panaitescu AM, Pavel B, Zagrean L, Peltecu G, Zagrean AM. Getting an Early Start in Understanding Perinatal Asphyxia Impact on the Cardiovascular System. Front Pediatr 2020;8:68. [PMID: 32175294 DOI: 10.3389/fped.2020.00068] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 5.5] [Reference Citation Analysis]
155 Thoré P, Girerd B, Jaïs X, Savale L, Ghigna M, Eyries M, Levy M, Ovaert C, Servettaz A, Guillaumot A, Dauphin C, Chabanne C, Boiffard E, Cottin V, Perros F, Simonneau G, Sitbon O, Soubrier F, Bonnet D, Remy-jardin M, Chaouat A, Humbert M, Montani D. Phenotype and outcome of pulmonary arterial hypertension patients carrying a TBX4 mutation. Eur Respir J 2020;55:1902340. [DOI: 10.1183/13993003.02340-2019] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
156 Welch CL, Chung WK. Genetics and Other Omics in Pediatric Pulmonary Arterial Hypertension. Chest 2020;157:1287-95. [PMID: 32006592 DOI: 10.1016/j.chest.2020.01.013] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
157 Chalmers JD, Reeves EL, Bullen NJ, Kolb M. The evolution of the European Respiratory Journal: ready for the new decade! Eur Respir J 2020;55:1902503. [PMID: 31974124 DOI: 10.1183/13993003.02503-2019] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
158 Frank BS, Ivy DD. Pediatric Pulmonary Arterial Hypertension: Evaluation and Treatment. Curr Treat Options Peds 2020;6:12-28. [DOI: 10.1007/s40746-020-00186-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
159 Welch CL, Austin ED, Chung WK. Genes that drive the pathobiology of pediatric pulmonary arterial hypertension. Pediatr Pulmonol 2021;56:614-20. [PMID: 31917901 DOI: 10.1002/ppul.24637] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
160 Shu LP, Zhang RH, Cai YH, Zhou JB, Yang JK, Qi L. Maternal Diabetes Mellitus and Persistent Pulmonary Hypertension of the Newborn: Accumulated Evidence From Observational Studies. Can J Diabetes 2020;44:327-334.e3. [PMID: 31902718 DOI: 10.1016/j.jcjd.2019.10.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
161 Ivy D, Beghetti M, Juaneda-simian E, Miller D, Lukas MA, Ioannou C, Okour M, Narita J, Berger RM. A Randomized Study of Safety and Efficacy of Two Doses of Ambrisentan to Treat Pulmonary Arterial Hypertension in Pediatric Patients Aged 8 Years up to 18 Years. The Journal of Pediatrics: X 2020;5:100055. [DOI: 10.1016/j.ympdx.2020.100055] [Reference Citation Analysis]
162 Sherlock LG, Wright CJ, Kinsella JP, Delaney C. Inhaled nitric oxide use in neonates: Balancing what is evidence-based and what is physiologically sound. Nitric Oxide 2020;95:12-6. [PMID: 31866361 DOI: 10.1016/j.niox.2019.12.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
163 Varghese N, Rios D. Pulmonary Hypertension Associated with Bronchopulmonary Dysplasia: A Review. Pediatr Allergy Immunol Pulmonol 2019;32:140-8. [PMID: 31871821 DOI: 10.1089/ped.2018.0984] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
164 Calcaterra G, Bassareo PP, Barilla F, Martino F, Fanos V, Fedele F, Romeo F. Pulmonary hypertension in paediatrics. A feasible approach to bridge the gap between real world and guidelines. J Matern Fetal Neonatal Med 2019;:1-211. [PMID: 31744358 DOI: 10.1080/14767058.2019.1695770] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
165 Levy PT, Jain A, Nawaytou H, Teitel D, Keller R, Fineman J, Steinhorn R, Abman SH, McNamara PJ; Pediatric Pulmonary Hypertension Network (PPHNet). Risk Assessment and Monitoring of Chronic Pulmonary Hypertension in Premature Infants. J Pediatr 2020;217:199-209.e4. [PMID: 31735418 DOI: 10.1016/j.jpeds.2019.10.034] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
166 Apitz C, Abdul-khaliq H, Albini S, Beerbaum P, Dubowy KO, Gorenflo M, Hager A, Hansmann G, Hilgendorff A, Humpl T, Kaestner M, Koestenberger M, Kozlik-feldmann R, Latus H, Michel-behnke I, Miera O, Quandt D, Sallmon H, Schranz D, Schulze-neick I, Stiller B, Warnecke G, Pattathu J, Lammers AE. Neue hämodynamische Definition der pulmonalen Hypertonie: Kommentar der Arbeitsgemeinschaft Pulmonale Hypertonie der Deutschen Gesellschaft für Pädiatrische Kardiologie und angeborene Herzfehler e. V. (DGPK). Monatsschr Kinderheilkd 2020;168:252-6. [DOI: 10.1007/s00112-019-00792-z] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
167 Goldberg L, Krauthammer A, Ashkenazi M, Soudack M, Tokatly Latzer I, Vardi A, Paret G. Predictors for plication performance following diaphragmatic paralysis in children. Pediatr Pulmonol 2020;55:449-54. [PMID: 31589009 DOI: 10.1002/ppul.24539] [Reference Citation Analysis]
168 Sallmon H, Moledina S, Albert DC, Beghetti M, Berger RMF, Bonnet D, Bukova M, Koestenberger M, Meinel K, Reinhardt Z, Tulloh RMR, de Wolf D, Hansmann G. Recommendations from the Association for European Paediatric and Congenital Cardiology for training in pulmonary hypertension. Cardiol Young 2019;29:1323-7. [PMID: 31554525 DOI: 10.1017/S104795111900235X] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
169 Haarman MG, Kerstjens-frederikse WS, Berger RM. The ever-expanding phenotypical spectrum of human TBX4 mutations: from toe to lung. Eur Respir J 2019;54:1901504. [DOI: 10.1183/13993003.01504-2019] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
170 Hsiao HF, Yang MC, Lai MY, Chu SM, Huang HR, Chiang MC, Fu RH, Hsu JF, Tsai MH. The Off-Label Use of Inhaled Nitric Oxide as a Rescue Therapy in Neonates with Refractory Hypoxemic Respiratory Failure: Therapeutic Response and Risk Factors for Mortality. J Clin Med 2019;8:E1113. [PMID: 31357613 DOI: 10.3390/jcm8081113] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
171 Beghetti M, Gorenflo M, Ivy DD, Moledina S, Bonnet D. Treatment of pediatric pulmonary arterial hypertension: A focus on the NO-sGC-cGMP pathway. Pediatr Pulmonol 2019;54:1516-26. [PMID: 31313530 DOI: 10.1002/ppul.24442] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
172 Hansmann G, Koestenberger M, Alastalo TP, Apitz C, Austin ED, Bonnet D, Budts W, D'Alto M, Gatzoulis MA, Hasan BS, Kozlik-Feldmann R, Kumar RK, Lammers AE, Latus H, Michel-Behnke I, Miera O, Morrell NW, Pieles G, Quandt D, Sallmon H, Schranz D, Tran-Lundmark K, Tulloh RMR, Warnecke G, Wåhlander H, Weber SC, Zartner P. 2019 updated consensus statement on the diagnosis and treatment of pediatric pulmonary hypertension: The European Pediatric Pulmonary Vascular Disease Network (EPPVDN), endorsed by AEPC, ESPR and ISHLT. J Heart Lung Transplant 2019;38:879-901. [PMID: 31495407 DOI: 10.1016/j.healun.2019.06.022] [Cited by in Crossref: 78] [Cited by in F6Publishing: 116] [Article Influence: 26.0] [Reference Citation Analysis]
173 Caicedo L, Hopper RK, Garcia H, Ivy DD, Haag D, Fineman J, Humpi T, Al-Tamimi O, Feinstein J, Berger RM, Berman-Rosenzweig E, Kashour T, Diaz GF, Mendoza A, Bobhate P, Handler S, Lopes AA, Barwad P, Kumar Rahit M, Krishnan U, Adatia ITK, Moledina S, Abman S, Cerro Marin MJD. EXPRESS: Acute Vasoreactivity Testing in Pediatric Idiopathic Pulmonary Arterial Hypertension: an international Survey on Current Practice. Pulm Circ 2019;:2045894019857533. [PMID: 31144586 DOI: 10.1177/2045894019857533] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
174 Koestenberger M, Sallmon H, Avian A, Cantinotti M, Gamillscheg A, Kurath-Koller S, Schweintzger S, Hansmann G. Ventricular-ventricular interaction variables correlate with surrogate variables of clinical outcome in children with pulmonary hypertension. Pulm Circ 2019;9:2045894019854074. [PMID: 31099302 DOI: 10.1177/2045894019854074] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
175 El-Kersh K, Homsy E, Daniels CJ, Smith JS. Partial anomalous pulmonary venous return: A case series with management approach. Respir Med Case Rep 2019;27:100833. [PMID: 31008046 DOI: 10.1016/j.rmcr.2019.100833] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
176 Calcaterra G, Fanos V, Bassareo PP. Still puzzling about a clear definition of pulmonary arterial hypertension in newborns. Eur Respir J 2019;53:1900005. [DOI: 10.1183/13993003.00005-2019] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
177 Rosenzweig EB, Abman SH, Berger RMF. Response: Still puzzling about a clear definition of pulmonary arterial hypertension in newborns. Eur Respir J 2019;53:1900135. [PMID: 30923178 DOI: 10.1183/13993003.00135-2019] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
178 Kiely DG, Levin D, Hassoun P, Ivy DD, Jone PN, Bwika J, Kawut SM, Lordan J, Lungu A, Mazurek J, Moledina S, Olschewski H, Peacock A, Puri GD, Rahaghi F, Schafer M, Schiebler M, Screaton N, Tawhai M, Van Beek EJ, Vonk-Noordegraaf A, Vanderpool RR, Wort J, Zhao L, Wild J, Vogel-Claussen J, Swift AJ. EXPRESS: Statement on imaging and pulmonary hypertension from the Pulmonary Vascular Research Institute (PVRI). Pulm Circ 2019;:2045894019841990. [PMID: 30880632 DOI: 10.1177/2045894019841990] [Cited by in Crossref: 34] [Cited by in F6Publishing: 51] [Article Influence: 11.3] [Reference Citation Analysis]
179 Simonneau G, Montani D, Celermajer DS, Denton CP, Gatzoulis MA, Krowka M, Williams PG, Souza R. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J 2019;53:1801913. [PMID: 30545968 DOI: 10.1183/13993003.01913-2018] [Cited by in Crossref: 957] [Cited by in F6Publishing: 1298] [Article Influence: 319.0] [Reference Citation Analysis]
180 Galiè N, McLaughlin VV, Rubin LJ, Simonneau G. An overview of the 6th World Symposium on Pulmonary Hypertension. Eur Respir J 2019;53:1802148. [PMID: 30552088 DOI: 10.1183/13993003.02148-2018] [Cited by in Crossref: 131] [Cited by in F6Publishing: 168] [Article Influence: 43.7] [Reference Citation Analysis]